What Do We Offer?
FutuRx provides a unique hands-on model for supporting early stage innovation, by combining the expertise of FutuRx’s management team with the global capabilities of its partners – Johnson & Johnson Innovation – JJDC, Takeda Ventures Inc.- TVI, OrbiMed Israel Partners and Leaps by Bayer teamed with the Incubators Incentive Program of the Israeli Innovation Authority.
The support of the R&D teams of Takeda, Johnson & Johnson and Bayer throughout the project selection process and during the first steps of each portfolio company, impacts the efficient translation of innovative breakthroughs to successful ventures and clinically meaningful products.
FutuRx provides 360 degree support to its portfolio companies, that benefit from the unique international cooperation of its partners, a comprehensive dedicated team of experts and financing ecosystem.
Companies established by FutuRx benefit from all aspects and professional assistance necessary in order to facilitate the development of innovative technologies, towards potentially becoming cutting-edge products for the benefit of patients and healthcare providers.
Infrastructure
FutuRx boasts a state of the art, 1200sqm facility complete with offices and fully equipped laboratories
Mentoring and Guidance
Our portfolio companies enjoy the accumulated years of experience of the FutuRx team, our Scientific Advisory Board (SAB) and international pharma partners in drug-development, industry-standard laboratory practices and project-management. The close involvement of our partners and SAB, allows for hands-on mentoring and exchange of ideas with big pharma. In addition, they also benefit from a strong support network of peers and consultants
Operational and administrative support
We provide our portfolio companies with BD, R&D, finance and accounting services, intellectual property strategy as well as legal, IT, administration and HR services
Network
FutuRx facilitates access to potential collaborators investors and stakeholders, key opinion leaders, clinical and regulatory consultants as well as service providers
Incubation for 3 years
Each company receives seed funding of $3.0 million from the Israeli Innovation Authority, our partners and the RMGP biopharma investment fund
Support for follow-on funding rounds
Graduating companies are matched with relevant investors from our strong investor base and focused business development efforts